Jasper Therapeutics Inc (NASDAQ:JSPR) has a beta value of 2.19 and has seen 3.12 million shares traded in the last trading session. The company, currently valued at $124.45M, closed the last trade at $8.30 per share which meant it lost -$9.41 on the day or -53.16% during that session. The JSPR stock price is -273.61% off its 52-week high price of $31.01 and 20.36% above the 52-week low of $6.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.32 million shares traded. The 3-month trading volume is 281.61K shares.
The consensus among analysts is that Jasper Therapeutics Inc (JSPR) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.26.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Sporting -53.16% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the JSPR stock price touched $8.30 or saw a rise of 63.14%. Year-to-date, Jasper Therapeutics Inc shares have moved -61.20%, while the 5-day performance has seen it change -61.20%. Over the past 30 days, the shares of Jasper Therapeutics Inc (NASDAQ:JSPR) have changed -63.10%. Short interest in the company has seen 2.07 million shares shorted with days to cover at 10.97.
Wall Street analysts have a consensus price target for the stock at $63, which means that the shares’ value could jump 86.83% from current levels. The projected low price target is $63.0 while the price target rests at a high of $63.0. In that case, then, we find that the current price level is -659.04% off the targeted high while a plunge would see the stock gain -659.04% from current levels.
Jasper Therapeutics Inc (JSPR) estimates and forecasts
Figures show that Jasper Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -58.25% over the past 6 months, with this year growth rate of 27.51%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
JSPR Dividends
Jasper Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
Insiders own 1.28% of the company shares, while shares held by institutions stand at 98.74% with a share float percentage of 100.02%. Investors are also buoyed by the number of investors in a company, with Jasper Therapeutics Inc having a total of 113.0 institutions that hold shares in the company.
